Time for a Fully Integrated Nonclinical–Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M. Vargas, Jean‐Pierre Valentin, Todd Wisialowski et al.|Clinical Pharmacology & Therapeutics|2020Cited by 96